Aviva PLC Alkermes Plc. Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

A detailed history of Aviva PLC transactions in Alkermes Plc. stock. As of the latest transaction made, Aviva PLC holds 23,194 shares of ALKS stock, worth $713,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,194

Previous 25,616 9.46%

Holding current value

$713,447

Previous $617,000 5.19%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $55,730 - $69,148	-2,422 Reduced 9.46%	23,194 $649,000
Q2 2024 Aug 02, 2024	BUY	$23.21 - $27.24 $82,349 - $96,647	3,548 Added 16.08%	25,616 $617,000
Q1 2024 May 14, 2024	BUY	$26.4 - $32.56 $582,595 - $718,534	22,068 New	22,068 $597,000
Q3 2019 Nov 12, 2019	SELL	$19.51 - $24.28 $1.11 Million - $1.39 Million	-57,045 Closed	0 $0
Q2 2019 Jul 30, 2019	SELL	$21.47 - $37.33 $30,680 - $53,344	-1,429 Reduced 2.44%	57,045 $1.29 Million
Q1 2019 May 14, 2019	BUY	$28.4 - $36.49 $28,428 - $36,526	1,001 Added 1.74%	58,474 $2.13 Million
Q4 2018 Feb 12, 2019	SELL	$27.94 - $44.61 $461,540 - $736,912	-16,519 Reduced 22.33%	57,473 $1.7 Million
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $103,409 - $123,555	-2,679 Reduced 3.49%	73,992 $3.14 Million
Q2 2018 Aug 01, 2018	SELL	$40.56 - $51.36 $45,913 - $58,139	-1,132 Reduced 1.45%	76,671 $3.16 Million
Q1 2018 May 14, 2018	SELL	$53.61 - $67.26 $376,878 - $472,837	-7,030 Reduced 8.29%	77,803 $4.51 Million
Q4 2017 Feb 13, 2018	SELL	$47.69 - $55.39 $340,792 - $395,816	-7,146 Reduced 7.77%	84,833 $4.64 Million
Q3 2017 Nov 13, 2017	BUY	$49.16 - $54.45 $187,791 - $207,999	3,820 Added 4.33%	91,979 $4.68 Million
Q2 2017 Aug 07, 2017	BUY	N/A	88,159	88,159 $5.11 Million

Others Institutions Holding ALKS

# of Institutions

361

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.05B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account